Biomarker Commons

Precision Therapeutics, Inc. has recently expanded their BioSpeciFx product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision's approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test.

Inc. Magazine has ranked Precision Therapeutics 293rd on its prestigious list of the 500 fastest growing privately owned companies in the U.S. with a three year annual compound growth rate of 79 percent. This award recognizes the significant accomplishments of the fastest-growing privately held entrepreneurial companies in America, whose performances have established them among the best in their industries. Precision was recognized as one of the top 31 companies in the healthcare industry.